Puerto Rico vaults to #1 in Brazilian pharmaceutical exports in 2026

Puerto Rico was barely on the map as a pharmaceutical export destination for Brazil. Through the first four months of 2026 — measured against the same period in 2025 — it climbed from #9 to #1, with US$ 113 million in shipments and a 12.4% share of Brazilian pharmaceutical exports. FOB value roughly tripled.

The fight for the top

A year ago, Puerto Rico generated US$ 35.8 million and held a 4.3% slice of the ranking. In one cycle, it displaced every peer above it. That is not a small correction — it is a structural repositioning that rewrites how Brazil's pharmaceutical exporters should think about the Caribbean corridor.

The island hosts one of the world's densest concentrations of pharmaceutical manufacturing. Major multinationals operate large-scale plants in Barceloneta and San Juan, and the island accounts for roughly half of all U.S. pharmaceutical exports by value. Part of what Brazil ships there may move further as re-exports or intermediary processing before reaching final U.S. consumers — which adds a strategic dimension to the trade lane.

Operational impact

For Brazilian pharmaceutical exporters, the air corridor via Miami and JFK is mature and reliable. The port of Santos handles heavier or refrigerated shipments when air freight costs are prohibitive. Anvisa holds partial mutual recognition agreements with the FDA, which lowers the compliance cost of product approvals for companies that already hold U.S. clearances.

The FX backdrop is not irrelevant. The real has stayed weak relative to the dollar through the window in question, which improves Brazilian manufacturers' price competitiveness when Puerto Rican buyers compare bids from multiple source markets.

Concentration risk

A 12.4% share concentrated in one partner is high enough to warrant a diversification check. If Puerto Rico functions partly as a re-export hub — and given the multinational footprint there, that is likely for a portion of the flow — a procurement-policy shift at one or two large groups could reverse the trajectory fast.

The question worth asking is which sub-segment of pharmaceuticals is driving the jump. Generic high-volume lines have more durable demand curves than contract batches tied to a specific molecule or registration cycle. Without the six-digit breakdown, the sustainability of the move remains uncertain.

Exporters who have grown in this lane should track monthly updates on Kyrodata to see whether Q2 2026 data confirms the pace or reveals concentration in a single shipment cluster from January to April.